Lung Carcinoma

A 57-year old male with no significant smoking history presented with lung squamous cell carcinoma in the right lung. Oncomine Dx Target Test was done and revealed EGFR exon 19 deletion and de novo EG… (full text at CIViC)

PMID 37641467 · Maeda et al., 2023 · Open in CIViC

In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the develo… (full text at CIViC)

PMID 26269204 · Planchard et al., 2015 · Open in CIViC

Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the d… (full text at CIViC)

PMID 24893891 · Cross et al., 2014 · Open in CIViC

For cells harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell l… (full text at CIViC)

PMID 26515464 · Hirano et al., 2015 · Open in CIViC

In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.

PMID 25923550 · Sequist et al., 2015 · Open in CIViC

Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed. in May 2016, after receiving a negative reply from the … (full text at CIViC)

PMID 27785053 · Van Der Steen et al., 2016 · Open in CIViC

CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of m… (full text at CIViC)

PMID 24065731 · Walter et al., 2013 · Open in CIViC

In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.

PMID 24658966 · Ai et al., 2014 · Open in CIViC

A 53-year-old Chinese man, a lifelong non-smoker, presented with chest tightness and pain. CT imaging revealed multiple small nodules in the right lower lobe of the lung. A biopsy confirmed stage IV l… (full text at CIViC)

PMID 38074875 · Xiang et al., 2023 · Open in CIViC

This phase 3 trial (NCT02151981) involved 419 patients with EGFR T790M mutant NSCLC who progressed after first-line EGFR inhibitor therapy (gefitinib, erlotinib, or afatinib) and were either treated w… (full text at CIViC)

PMID 27959700 · Mok et al., 2017 · Open in CIViC

Case report of a patient with stage IV lung adenocarcinoma and a 15–base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After fur… (full text at CIViC)

PMID 26181354 · Yu et al., 2015 · Open in CIViC

Case report of a patient with stage IV lung adenocarcinoma and a 15–base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After fur… (full text at CIViC)

PMID 26181354 · Yu et al., 2015 · Open in CIViC

A 53-year old man (non-smoker) presented with chest tightness and pain and was revealed to have stage IV lung adenocarcinoma with EGFR exon 19 deletion. The patient started first-line Erlotinib at 150… (full text at CIViC)

PMID 38074875 · Xiang et al., 2023 · Open in CIViC

A patient was initially diagnosed with stage IIIA lung adenocarcinoma with EGFR L858R and was treated with lobectomy and adjuvant pemetrexed and cisplatin. 20 months later the patient had recurrent di… (full text at CIViC)

PMID 35004270 · Wang et al., 2021 · Open in CIViC

In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have T847I mutation, and was treated with the 1st generation TKI gefitinib. The pati… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a lung adenocarcinoma patient with EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitor) and EGFR T854A co-mutation, EGFR T854A was reported to be refractory to erlotinib trea… (full text at CIViC)

PMID 19010870 · Bean et al., 2008 · Open in CIViC

One case with presumably EGFR::USP42 fusion was mentioned in OrigiMed database of Chinese patients with lung adenocarcinoma. EGFR breakpoint in intron 27.

PMID 31064887 · Guan et al., 2019 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V742A mutation, and was treated with the 1st generation TKI gefitinib. The patient (M,… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In an advanced lung adenocarcinoma patient with EGFR V769A mutation, EGFR V769A was reported to be sensitive to erlotinib treatment. The patient was treated with 1st-line standard chemotherapy, radiot… (full text at CIViC)

PMID 24908064 · Xing et al., 2014 · Open in CIViC

In this meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, 1 patient with V769_770insASV had overall and progression-free survival of 642 days. From this and literature review it… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

A 60 year old female former smoker with 2 pack years and EGFR V769_D770insASV lung adenocarcinoma patient was given erlotinib as first line treatment, and had progressive disease as best response with… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

An in vitro study treated Ba/F3 murine cells (IL-3 dependent lymphocyte model) to afatinib, a second-generation tyrosine kinase inhibitor (TKI), for several weeks. Secondary resistant mutations to afa… (full text at CIViC)

PMID 40940797 · Oiki et al., 2025 · Open in CIViC

In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774A mutation, and was treated with the 1st generation TKI gefitinib. The patient (F,… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a lung adenocarcinoma patient harboring EGFR V774_C775insHV mutation, EGFR V774_C775insHV was associated with lack of response to treatment with erlotinib monotherapy.

PMID 23371856 · Arcila et al., 2013 · Open in CIViC

MCF-7 cells were transduced with YFP tagged EGFR with D770_N771INSSVD mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased… (full text at CIViC)

PMID 17877814 · de Gunst et al., 2007 · Open in CIViC

In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib. T… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V834I mutation, and was treated with the 1st generation TKI gefitinib. The pati… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V851I mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

Using NGS, genomic profiling from tumor/plasma biopsies from 17,442 Chinese lung cancer patients was performed. EGFR::VSTM2A reported in 2/1053 recurrent kinase fusions in lung cancer (NSCLC, adenocar… (full text at CIViC)

PMID 34508169 · Li et al., 2021 · Open in CIViC

Deguelin inhibits EGFR signaling in wild-type NSCLC cells. It reduces EGFR phosphorylation and downstream signalling, as shown by decreased phosphorylation of Akt and ERK1/2. This effect was not obser… (full text at CIViC)

PMID 32081857 · Gao et al., 2020 · Open in CIViC

In a phase 3 clinical trial of East Asian pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response compared to … (full text at CIViC)

PMID 19692680 · Mok et al., 2009 · Open in CIViC

While EGFR mutation is a strong predictive factor for EGFR inhibition, some patients with EGFR wild-type also respond. The authors investigated whether phosphorylated EGFR could be a potential predic… (full text at CIViC)

PMID 22901364 · Wang et al., 2012 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR Y764_V765insHH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.845�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

A 66 year old male with 10 pack year smoking history and lung adenocarcinoma with EGFR Y764_V765insHH mutation was given gefitinib as first line treatment, and had stable disease as best response with… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

An EGFR::YAP1 fusion was reported in a patient with non-small cell lung cancer. The breakpoint in EGFR is given as exon 26. Breakpoint in YAP1 is not specified.

PMID 31064887 · Guan et al., 2019 · Open in CIViC

This is a case report of a patient with lung adenocarcinoma harboring EGFR::RAD51 fusion, however describes other EGFR fusions in lung adenocarcinoma. The authors examined data from the database of Or… (full text at CIViC)

PMID 31064887 · Guan et al., 2019 · Open in CIViC

In the PROFILE 1001 study, from 31 NSCLC tumors positive for ALK fusions with sufficient material for RT-PCR aided exon breakpoint identification, 1 case of EML4-ALK variant 2 (EML4 exon 20 fused to A… (full text at CIViC)

PMID 20979469 · Kwak et al., 2010 · Open in CIViC

EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) were expressed in Ba/F3 cells using retrovirus. While all constructs rendered Ba/F3 cells IL3-independant, marked diff… (full text at CIViC)

PMID 22912387 · Heuckmann et al., 2012 · Open in CIViC

Multiplex RT-PCR to detect in-frame fusions of EML4 to ALK was performed on total RNA from 253 lung adenocarcinomas, and 9 samples were found to contain such fusions, one of which was a novel fusion c… (full text at CIViC)

PMID 18927303 · Takeuchi et al., 2008 · Open in CIViC

In a cohort of 75 NSCLC patients that had tested positive for 3 EML4-ALK rearrangements, two individuals were identified via RT-PCR with a novel EML4-ALK translocation involving the first 6 exons of E… (full text at CIViC)

PMID 18593892 · Choi et al., 2008 · Open in CIViC

In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684. Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon… (full text at CIViC)

PMID 18451166 · McDermott et al., 2008 · Open in CIViC